Posted April 20, 2012 in Uncategorized
HAYWARD, Calif., April 19, 2012 /PRNewswire/ — Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and a global market leader in aesthetic treatments, today announced the results of a first-of-its-kind, IRB-approved clinical study that evaluated the use of its novel 1440nm fractional laser to assess the effect of this treatment on the appearance of pores, skin texture and overall appearance of skin. The study utilized Solta’s newest fractional resurfacing platform, the Clear + Brilliant™ Laser System, which is used by clinicians worldwide to help patients prevent the initial signs of photo-aging, maintain the look and feel of their youthful appearance, and improve the texture and tone of aging and sun-damaged skin. The complete research findings will be presented at the 32nd American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Kissimmee, Fla. on April 18 through April 22, 2012.
The clinical study is the first to objectively measure the effects of a fractional device on facial pores. It included 20 patients (Fitzpatrick I-IV) who received six treatments spaced two weeks apart. Each patient received a full-face treatment consisting of eight passes at the highest tolerable energy level. A photographic assessment of facial pores using the VISIA-CR Imaging system was performed before treatment at each visit and subjective measurements were recorded by both the subject and investigator regarding pore appearance, appearance of skin texture, and overall skin appearance. After a series of six treatments, there was a significant reduction in pore score (p<<0.002) and investigators and subjects noted moderate-to-marked improvement in pore appearance, including pore count and size. Ninety-five percent of all patients treated reported visible improvement in pore appearance, with 60 percent reporting at least moderate-marked improvement. In addition, 100 percent of patients reported improvement in skin texture and overall appearance, with 90 percent reporting at least moderate-marked improvement. The treatment was well tolerated with some mild-moderate erythema and less-than-mild edema and there were no long term side effects and no serious adverse effects reported.
“This research is exciting since pore size has never been systematically studied before and it is such an area of concern for patients,” said clinical investigator Jeffrey S. Dover, M.D., Associate Clinical Professor of Dermatology, at Yale University School of Medicine, and co-founder of SkinCare Physicians, in Chestnut Hill, Mass. “The results demonstrate that Clear + Brilliant can improve not only the tone and texture of the skin, but also can significantly reduce both pore count and pore size in all skin types.”
Concannon Plastic Surgery has been proud to offer Clear + Brilliant for their patients, and he results have been very gratifying. To schedule an appointment for an evaluation and to learn more, contact us at 573-449-5000.